SENSEX NIFTY
YOU ARE HERE >  Moneycontrol Markets > Announcements Pharmaceuticals

Orchid Pharma

BSE: 524372|NSE: ORCHIDPHAR|ISIN: INE191A01019|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
May 25, 16:01
37.85
0.5 (1.34%)
VOLUME 54,391
LIVE
NSE
May 25, 16:01
37.90
0.6 (1.61%)
VOLUME 216,306
Announcements on Orchid Pharma

18th-May-2016 13:10Source: NSE

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange that the SEBI (Prohibition of Insider Trading) Regulations, the trading window for dealing in the securities of the Company shall remain closed for all ...

18th-May-2016 11:17Source: BSE

Orchid Pharma- Board Meeting Intimation for Results & Closure of Trading Window

Orchid Pharma Ltd has informed BSE that a meeting of the Board of Directors is proposed to be held on May 27, 2016, to approve the Audited financial results of the Company for the period from April 01...

11th-Apr-2016 11:44Source: BSE

Orchid Pharma- Updates

Orchid Pharma Ltd has informed BSE that Orchid received the Establishment inspection report (EIR) from USFDA based on the successful inspection closure for the API manufacturing facility located at Al...

11th-Apr-2016 11:27Source: NSE

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange that the Company received the Establishment inspection report (EIR) from USFDA based on the successful inspection closure for the API manufacturing faci...

17th-Mar-2016 13:48Source: BSE

Orchid Pharma- Orchid receives final USFDA nod for Rasagiline generic formulation

Orchid Pharma Ltd has informed BSE regarding a Press Release dated March 17, 2016 titled "Orchid receives final USFDA nod for Rasagiline generic formulation".

17th-Mar-2016 13:23Source: NSE

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange regarding a press release dated March 17, 2016 titled "Orchid receives final USFDA nod for Rasagiline generic formulation".

10th-Feb-2016 10:48Source: BSE

Orchid Pharma- Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

K Raghavendra Rao has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE

7th-Jan-2016 14:11Source: NSE

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange that Industrial Development Bank of India has withdrawn the nomination of Shri Nagaraj Garla and instead appointed Shri Rabinarayan Panda, Chief General...

7th-Jan-2016 13:37Source: BSE

Orchid Pharma- Change in Directorate

Orchid Pharma Ltd has informed BSE that Industrial Development Bank of India has withdrawn the nomination of Shri Nagaraj Garla and instead appointed Shri Rabinarayan Panda, Chief General Manager, IDB...

31st-Dec-2015 15:26Source: NSE

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange that the Company is pleased to announce that orchid received the Establishment Inspection Report (EIR) from USFDA based on the successful inspection clo...

1 2 3 4 5 Next >>
Board Meeting (Orchid Pharma)

Meeting Date

Remark

2016-05-27

Audited Results

Quick Links for Orchid Pharma
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.